Most overweight and obese patients with Type 1 or Type 2 diabetes are eligible to use OPTIFAST VLCD as part of an overall management program that emphasises the importance of ongoing weight maintenance. Special care is needed when managing patients with diabetes, as a VLED significantly reduces plasma glucose concentration independently of weight loss. For this reason, hypoglycaemia is likely to occur if insulin or sulphonylureas are not reduced or stopped. Please note that any adjustments to medication should only involve the Endocrinologist or doctor.
For further information regarding the management of patients with diabetes and using OPTIFAST VLCD, please refer to the OPTIFAST VLCD Management of Complex Cases Protocol in Resources section.